

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to § 240.14a-12

BIOGEN IDEC INC.

(Name of Registrant as Specified In Its Charter)

N.A.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
 - Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Total fee paid:
 - Fee paid previously with preliminary materials.
 - Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:
-



**Biogen Idec
Investor Presentation**

Spring 2009

biogen ideo

Forward Looking and Proxy Solicitation Statements

- This presentation includes forward-looking statements about:
 - our 2009 guidance and our financial and operational goals through 2010
 - estimates of sales for our products and the size and growth of the markets for our products
 - our expected filings with regulatory agencies
 - the anticipated development and timing of programs in our clinical pipeline
 - the sales potential of TYSABRI®
 - the availability of external growth opportunities
- Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those that we express or imply, including our continued dependence on our two principal products, AVONEX® and RITUXAN®, the uncertainty of success in commercializing other products including TYSABRI®, the occurrence of adverse safety events with our products, competitive pressures, changes in the availability of reimbursement for our products, our dependence on collaborations over which we may not always have full control, failure to execute our growth initiatives, possible adverse impact of government regulation, problems with our manufacturing processes and our reliance on third parties, the impact of the global credit crisis, the market, interest and credit risks associated with our portfolio of marketable securities, our significant investment in a manufacturing facility currently under development, our ability to attract and retain qualified personnel, the risks of doing business internationally, the actions of activist shareholders, fluctuations in our operating results, our ability to protect our intellectual property rights and the cost of doing so, product liability claims, fluctuations in our effective tax rate, our level of indebtedness, environmental risks, aspects of our corporate governance and collaborations and the other risks and uncertainties that are described in Item 1.A. Risk Factors in our annual report on Form 10-K and in other reports we file with the SEC.
- These forward-looking statements speak only as of the date of this presentation, and we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
- On April 27, 2009, Biogen Idec filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the Company's 2009 Annual Meeting. Biogen Idec's stockholders are strongly advised to read the definitive proxy statement carefully before making any voting or investment decision because the definitive proxy statement contains important information. The Company's proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC's web site at www.sec.gov or from Biogen Idec at <http://investor.biogenidec.com>. The Company's definitive proxy statement and other materials will also be available for free by writing to Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142 or by contacting our proxy solicitor, Innisfree M&A Incorporated, by toll-free telephone at (877) 750-5836.

Delivering on Our Commitment to Shareholders

Financial Performance

- Consistently delivered strong EPS and revenue growth over the last 5 years
- 2008 results exceeded guidance
- Solid growth projected for 2009; Q1 revenues +10% y/y, non-GAAP EPS +27% y/y
- Overseen successful merger and delivered on merger goals

Operational Performance

- Continuing to grow TYSABRI and effectively manage risk-benefit profile
- Viewed as having one of the most robust pipelines in industry
 - Progress in pipeline: 8 programs expected in registrational trials by year end 2009
 - Sustained R&D investment and operational efficiency

Corporate Governance

- Added two new directors after soliciting input from major shareholders
- Adopting majority vote for uncontested director elections
- Terminated the "poison pill" (shareholder rights plan)
- Unilaterally waived standstill agreements with participants in 2007 sale process
- \$3 billion share repurchase – 56M shares tendered July 2007


Accountability to Shareholders

- Maintained active dialogue with leading shareholders
- Enabled dialogue between shareholders and our directors
- Actively engaged in soliciting shareholder input

Agenda

- **Results and Accountability**
- **Drivers of Shareholder Value**
- **Corporate Governance**

Exceptionally Strong 2008






Substantially exceeded 2008 guidance

	Original Guidance	2008 Results
Revenue	\$3.6-\$3.8 billion	\$4.1 billion
Revenue Growth	15%-20%	29%
Non-GAAP Operating Margins	36%-40%	39%
Non-GAAP R&D	26%-28%	26%
Non-GAAP SG&A	21%-23%	22%
Non-GAAP EPS	\$3.20-\$3.35	\$3.66


Note: Non-GAAP EPS excludes the impact of purchase accounting, merger-related adjustments, stock option expense, and other items and their related tax effects. GAAP to non-GAAP EPS reconciliation is provided in the appendix at the end of this presentation.

Consistently Strong Track Record



Note: 2003 is pro forma data for the Biogen and Idec merger. EPS numbers are Non-GAAP which excludes the impact of purchase accounting, merger-related adjustments, stock option expense, and other items and their related tax effects. GAAP to non-GAAP EPS reconciliation is provided in the appendix at the end of this presentation. Free cash flow defined as cash flows from operations minus capital expenditures as disclosed on our Form 10-K

Diversified and Growing Portfolio




Note: Note: 2003 amounts represent pro forma information of the historical results of IDEC Pharmaceuticals Corporation and Biogen, Inc. giving effect to the merger as if it occurred on January 1, 2003.

biogen idec

Growing Pipeline Across All Phases

Number of Total Programs



Robust Growth Across all Phases of the Pipeline . . .

- In the past 5 years Biogen has added:
 - 18 programs at the discovery level
 - 23 early stage programs
 - 5 late stage programs

. . . Driven by Efficient Spend and an Effective Research Engine

- R&D spend has increased to drive pipeline growth, but not without significant results
 - R&D spend has doubled since 2003 while the number of programs has nearly tripled
 - R&D spend has grown from \$534M in 2003 to \$1.05B in 2008

Achieving Our 2010 Goals

We Made Substantial Progress Over The Past Year Toward Achieving Our 2010 goals

		Goal	Progress
Financial	Revenue Growth	• 15% top line CAGR from 2007 to 2010	✓+
	EPS Growth	• 20% bottom line CAGR from 2007 to 2010	✓+
Products	TYSABRI	• TYSABRI patients on therapy exceeds 100,000	✓-
	AVONEX	• AVONEX maintains its patient market share in the "ABCR" market	✓
	Anti-CD20 Franchise	• Anti-CD20 franchise growth fueled by filings in at least 2 additional indications	✓
	Geographic Mix	• Over 40% of revenue from international business	✓
Pipeline	New Products	• 2 new products or indications launched	✓+
	Development Status	• 6 programs in late stage development	✓+
	Acquisition Strategy	• Continued execution of disciplined external growth strategy	✓

Note: The bottom line, or EPS, reference in this slide refers to non-GAAP diluted EPS. Non-GAAP diluted EPS excludes the impact of purchase accounting, merger-related adjustments, stock option expense, and other items and their related tax effects. GAAP to non-GAAP EPS reconciliation is provided at the end of this presentation

biogen idec

External Validation

Pharmaceutical
Executive

PRODUCTS

- 2008 Best in Brand Comeback Award (TYSABRI)
- 2008 Pharmaceutical Executive Ad Stars Patient Power (TYSABRI)



Moody's Investors Service

PIPELINE

- Ranked #1 Late-Stage Pipeline Quality
- Ranked #4 Pipeline Diversity



PEOPLE

- Biogen Idec, International ranked fourth overall, second in pharma/biotech by Great Place To Work Institute



Pharmaceutical
Executive

PERFORMANCE


- Named to 2009 list of Forbes Global High Performers
- 2008 Pharmaceutical Executive Company of the Year

biogen idec

Biogen Idec Stock Performance (as of Record Date*)

Biogen Idec Has Outperformed Both the BTK and S&P 500 Since the 2003 Merger

Biogen Idec Stock Price History



	CAGR		
	BIIB	BTK	S&P 500
Since Merger	8%	6%	-4%
5 Years	-2%	3%	-6%
3 Years	4%	-3%	-14%
1 Year	-22%	-20%	-39%

Note: Record Date April 6, 2009

biogen idec

Winning Strategy



Transforming Discovery Into Care

AVONEX[®]
(interferon beta-1a)



Leading worldwide therapy for MS

TYSABRI[®]
(natalizumab)




*Breakthrough MS therapy –
Powerful Efficacy*

Rituxan[®]
Rituximab



Standard of care for NHL


Strategy Drives Economic Model



Source: Company annual filings and 2008 earnings transcripts
 *Genzyme based on 5/6/2009 Analyst Day reclassification of GAAP to Non-GAAP financial statements
 (1) Big Pharma average includes Pfizer, Merck, BMS, Eli Lilly, Schering-Plough

biogen idec


Drivers of Shareholder Value



TYSABRI Trajectory

TYSABRI \$900 million Annual Run Rate


Monthly Global Revenue Trajectory Post Launch



Top 20 Biologic Drugs
(\$ Revenues in Billions)

Enbrel	\$6.5B	Avonex	\$2.2B
Remicade	5.3B	Novolin	2.0B
Epogen/Procrit	5.1B	Lucentis	1.8B
Rituxan	5.1B	Humalog	1.7B
Humira	4.5B	Rebif	1.7B
Avastin	4.5B	NeoRecormo	1.5B
Herceptin	4.4B	Advate	1.5B
Aransep	3.3B	Erbitux	1.5B
Neulasta	3.3B	Betaseron	1.4B
Lantus	3.1B	Pegasys	1.4B

Physician Confidence Returning



TYSABRI Marketing Plan

Powerful Efficacy with Manageable Side Effects

REINFORCING BENEFIT

- Developed and implemented a global branding message supporting efficacy positioning
- Reinforced comfort with use through regular exposure and safety updates
- Further communicate TYSABRI's strong efficacy



Translate improved benefit/risk to increased and sustained use

REDUCING RISK

- Working to make PML a more detectable and manageable side effect
- Detectable through clinical vigilance
 - Identifying new methods of risk assessment, detection and management
- Available initial actions include:
 - Halting TYSABRI
 - Plasma Exchange (PLEX)
 - Mefloquine
- Post marketing experience is less than 1 in 1,000
- Outcomes better than expected

1) Munschauer et al. Natalizumab Significantly Increases the Cumulative Probability of Sustained Improvement in Physical Disability, Abstract #474 Presented at the World Congress on Treatment and Research in Multiple Sclerosis, September 2008, Montréal, Canada. Based on a post hoc subset analysis of two years. 2) Havrdova, et al. Lancet neurology February 9, 2006 S1474-4422(09)70021-3 : Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Free of disease activity defined as no activity in clinical measures or radiological measures. 3) Polman CH, et al. N Engl J Med. 2005;354:899-910.

biogen idec


TYSABRI Marketing Acceleration

Comprehensive Dialogue with Customers Builds Trust and Confidence




Potential Breakthrough in AVONEX Life Cycle Management

AVONEX Revenues



PEGylated Interferon Beta-1a molecule



Issued U.S. patent and pending applications world-wide

Enhancing Benefits of AVONEX

- PEGylated version of Interferon β -1a delivered via liquid prefilled syringe and SC administration
- Increased half-life and systemic exposure of the protein reduces frequency of injections
- May improve convenience and compliance for patients with MS who use Interferons

Phase 3

- Plan to initiate registration program mid-2009
 - Placebo-controlled study in MS; 1,260 patients
 - Primary endpoint: Annualized Relapse Rate at 1 year
- To test biweekly and monthly subcutaneous dosing

RITUXAN Growth


RITUXAN Hem/Onc US Product Revenues (\$B)



Anti-CD20 Adoption in RA

\$8B RA Market by 2012

**Immunology
Future Growth Driver**




M&A Focus for Creating Shareholder Value

- **We are exploring opportunities consistent with our strategy, which:**
 - **Include late stage assets and/or marketed products**
 - **Will increase revenue growth in the 2010-2013 time frame**
 - **Provide innovative products to address unmet needs**
 - **Can be commercialized via a specialty sales force**
 - **Are at attractive valuations**

Proven Track Record of Returning Cash to Shareholders if No Strategic Opportunity

Cash Balance Forecasted to be \$3.3 Billion at YE 2009



"We try to put ourselves in the seats of shareholders and what they would see as good value, both from an economic perspective as well as a strategic perspective."

- Paul Clancy CFO, Citi Biotech Day, 4/09

"...there are some attractive assets out there potentially, but we will continue to apply a very disciplined approach..."

- Jim Mullen, Cowen Healthcare Conference, 3/09

"We will continue, as we have in the past, to look at what is the best use of cash..."

- Jim Mullen, JP Morgan Healthcare Conference 1/09

"We are going to try to do what is best for shareholders, whether that's on the strategic front or returning [cash] to shareholders"

- Paul Clancy CFO Deutsche Bank Conference 11/08

- 1) Other investing/financing includes net sales of marketable securities and investments, net effects of exchange rate changes, collateral received under securities lending, and other investing activities.
- 2) Stock based compensation includes proceeds from issuance of stock for stock based compensation and excess tax benefits from share based compensation.

Value Creation Through R&D at Biogen Idec

World class biotherapeutic discovery and development organization with proven track record of delivering innovative molecules


Strong Scientific Expertise

Robust Clinical Development Capabilities





Therapeutic Area Alignment

Disciplined Investment Choices

First-in-Class and Best-in-Class Molecules



Broad and Deep Pipeline




Divested or Discontinued

Marketed – Amevive in Psoriasis, Zevalin in NHL
 Phase 2 or 3 – Rituxan in PMS, Rituxan in SLE, Barminecept in RA, Fostolizumab in Inflammatory Disorders, Tysabri in RA
 Phase 1 or Preclinical – LTβ in Solid Tumors, BAFF-R in Inflammatory Disorders, αβ6 in IPF, IFNβ Gene Delivery in Liver Metz


 January 2005 Pipeline
 Progress to date

biogen idec

Pipeline Supported by Active Business Development



Specialty Markets Focus Offers Superior Economics



R&D Accomplishments

60 clinical trials ongoing

- 6 programs in registrational trials and 2 more expected in 2009

***15 indications across neurology, oncology, immunology,
cardiovascular and hematology***

35 preclinical and discovery research programs

March 25, 2009 Investor R&D Day

Comments on Biogen Idec's Pipeline

"Diverse early stage pipeline beyond neurology."
Jim Birchenough (Barclays)

"Encouraged by pipeline progress since last R&D day (2007)."
Maged Shenouda (UBS)

"Broad and deep pipeline."
Eric Schmidt (Cowen)

"Pipeline is gaining visibility."
May Kin Ho (Goldman Sachs)

"R&D Day was largely a success...leaving us encouraged about several of the early stage programs, including Lingo, Neublabin and Factor IX."
Mike Aberman (Credit Suisse)

"R&D Day underscores expanding pipeline."
Joel Sendek (Lazard)

"Good R&D day. Deep and broad pipeline strengthens acquisition thesis."
Jason Zhang (BMO)

"Pipeline has a quality emerging cancer franchise."
Alex To (Natixis)

"Early stage pipeline is innovative."
Jason Kantor (RBC)

"Pipeline continues to show promise."
Ian Somaiya (Weisel)


"BIIB made the case that the story is more than Tysabri."
Chris Raymond (Baird)

Recognition of Pipeline Strength

Moody's Investors Service Research Rates Biogen Idec:

Highest on late-stage pipeline quality


Biogen Idec (Baa3)	54.3%
Allergan (A3)	31.8%
Schering-Plough (Baa1)	27.7%
J&J (Aaa) / Pharma Only**	27.5%
Amgen (A3)	23.8%
Genentech (A1*)	21.0%
Wyeth (A3*)	20.1%
Eli Lilly & Company (A1)	18.8%
Bristol-Myers Squibb (A2)	16.8%
Merck & Co., Inc. (Aa3)	16.5%
Abbott (A1) / Pharma Only**	14.2%
J&J (Aaa) / Total Company**	11.4%
Abbott (A1) / Total Company**	11.4%
Pfizer (Aa1*)	10.0%



 * Ratings under review
 ** Ratios shown on both bases for J&J and Abbott

Most pipeline diversity

Merck & Co., Inc. (Aa3)	17.4%
Pfizer (Aa1*)	20.6%
Wyeth (A3*)	21.7%
Biogen Idec (Baa3)	22.5%
Schering-Plough (Baa1)	26.1%
Johnson & Johnson (Aaa)	26.7%
Bristol-Myers Squibb (A2)	29.0%
Abbott Laboratories (A1)	29.6%
Genentech (A1*)	35.5%
Allergan (A3)	35.7%
Eli Lilly & Company (A1)	39.2%
Amgen (A3)	83.9%



 * Ratings under review

Issuer Scorecard: Large U.S. Pharmaceutical Companies published February 2009

- Most recent rating methodology mapping for 12 large U.S.-based pharmaceutical and biotech companies
- Ranking of the 12 companies from strongest to weakest on several important criteria

Biogen Idec Board of Directors Has Owners' Perspective

Steward of Shareholder Value

- Largest merger of 2 independent biotechs
- \$3B share repurchase/Dutch Auction
- Review of strategic alternatives; including sale of the company
- Disciplined execution of business development strategy


Strong Corporate Governance

- Added 2 new directors after soliciting input from major shareholders
- 5 new directors out of 13 since 2006
- Adopting majority voting for uncontested director elections
- Terminated the "poison pill"

Financial Discipline

- Exceeded 17% top-line and 25% bottom-line goal from merger to 2008
- 2005 reduction in force (17%)
- Divestiture of non-core assets
- Credit rating upgrade by S&P to BBB+
- Cash position of \$2.5B⁽¹⁾ as of March 31, 2009

Maximizing Shareholder Value



Biogen Idec Board of Directors Has Broad Based Experience

	General Mgmt	Finance / M&A	R&D	Customer Perspective / Market & Sales	International Business	Public Policy	Nobel Laureate / Natl Academy of Sciences
Larry Best*		✓			✓	✓	
Alan Glassberg, M.D.*			✓	✓			
Robert Pangia*	✓	✓					
Bill Young*	✓	✓	✓	✓			✓
Jim Mullen	✓	✓		✓	✓	✓	
Bruce Ross	✓		✓	✓		✓	
Phil Sharp, Ph.D.			✓				✓
Lynn Schenk						✓	
Recent Additions							
Cecil Pickett, Ph.D. (2006)	✓		✓		✓		✓
Marijn Dekkers Ph.D. (2007)	✓	✓		✓	✓		
Nancy Leaming (2008)	✓	✓		✓		✓	
Stelios Papadopoulos, Ph.D. (2008)	✓	✓	✓				
Brian Posner (2008)	✓	✓		✓			

* Standing for election

biogen idec

Board Additions Reflect Diversified Expertise and Shareholder Input

Cecil B. Pickett, Ph. D.
(July 2006)

- President, Research and Development Biogen Idec
- 28 years experience at Schering-Plough and Merck

Marijn E. Dekkers, Ph. D.
(June 2007)

- President, CEO, and Director Thermo Fisher Scientific
- 15 years experience at Honeywell and General Electric

Nancy L. Leaming
(January 2008)

- 22 years as senior executive at Tufts Health Plan
 - Former President and CEO of Tufts Health Plan

Stelios Papadopoulos, Ph. D.
(June 2008)

- 19 years experience in investment banking with focus on biotechnology and pharmaceuticals
 - Former Vice Chairman of Cowen & Co.
 - Former Chairman of PaineWebber Development Corp
- Adjunct Associate Professor of Cell Biology at NYU Medical Center
- Co-founder/Board member of numerous biotech companies

Brian S. Posner
(July 2008)

- Over 20 years of experience in investment management
 - Former CEO and co-Chief Investment Officer, ClearBridge Advisors
 - Former Portfolio Manager and Analyst at Fidelity Investments
- Co-founder of hedge fund, Hygrove Partners

biogen idec





Dissident Slate

	<u>Age</u>	<u>Primary Occupation</u>	<u>Previous Board</u>	<u>Seeking Board</u>
Alexander J. Denner, Ph.D.	39	Managing Director, Icahn Partners	ImClone	Biogen Idec, Enzon*, Amylin
Richard C. Mulligan, Ph.D.	54	Professor, Harvard Medical School	ImClone, Somatix	Biogen Idec, Enzon*
Thomas F. Deuel, M.D.	74	Professor, Scripps Research Institute	ImClone	Biogen Idec, Amylin
David Sidransky, M.D.	48	Professor, Johns Hopkins	ImClone, Xenomics, Alfacell	Biogen Idec, Amylin

- Nominees have served or will serve together (ImClone, Enzon, Amylin)
- Dissident slate would weaken Board's financial and operational capabilities
- Under the Company's Corporate Governance Guidelines, one of the nominees would be unable to serve for a full term

* Elected in January 2009 to Enzon Board of Directors

Biogen Idec Actively Engages in Dialogue with Shareholders

	Conferences & Roundtables	Roadshows	Buy-side Meetings	Phone Contacts
				
Independent Directors	✓	✓	✓	
CEO / CFO	✓	✓	✓	
Investor Relations	✓	✓	✓	✓
	<ul style="list-style-type: none"> • Sell Side Conferences and R&D Roundtables – 20 in 2007 – 16 in 2008 	<ul style="list-style-type: none"> • Proxy Roadshow in 2008 • Non-Deal Roadshows 	<ul style="list-style-type: none"> • In Person Meetings – 300+/year 	<ul style="list-style-type: none"> • Phone Contacts – 1,000+/year

Board receives shareholder input on a regular basis



Delivering on Our Commitment to Shareholders

Financial Performance

- Strong 2008 performance and effective utilization of capital
- Overseen successful merger and delivered on merger goal



Operational Performance

- Focused on our 2010 goals and advancing our R&D pipeline for future growth



Corporate Governance

- Proactively strengthened our board and improved our corporate governance



Accountability to Shareholders

- Maintained an active dialogue with our shareholders and solicited and acted on shareholder input



Conclusion

- Biogen Idec has a proven track record of delivering exceptional performance
- The business is poised to create future shareholder value
 - Executing a well-defined strategy for future growth
 - Broad and deep pipeline with 8 late stage programs expected 2H 2009
- This Board is best positioned to continue to deliver value to all shareholders
 - Active, engaged
 - Proactively evaluate ways to maximize shareholder value
 - Exceptional steward of value and capital

Vote for Our Nominees on the White Proxy Card

GAAP to non-GAAP Reconciliation

Diluted EPS and Net Income Attributable to Biogen Idec Inc

Condensed Consolidated Statements of Income – Operating Basis	FY 2003	FY 2004	FY 2005	FY 2006	FY 2007	FY 2008
GAAP diluted EPS	(4.92)	0.07	0.47	0.63	1.99	2.65
Adjustment to net income attributable to Biogen Idec Inc. (see below)	6.14	1.38	1.10	1.62	0.75	1.01
Effect of FAS128 and EITF 0306	-	(0.05)	-	-	-	-
Non-GAAP diluted EPS	1.22	1.40	1.57	2.25	2.74	3.66
GAAP Net Income Attributable to Biogen Idec Inc. (\$M)	(875.1)	25.1	160.7	217.5	638.2	783.2
Revenue – Pre-merger Biogen product, royalty and corporate partner revenue	1,173.1	-	-	-	-	-
COGS – Fair value step up of inventory acquired from Biogen and Fumapharm	231.6	295.5	34.2	7.8	-	-
COGS – Pre-merger Biogen cost of sales	(179.2)	-	-	-	-	-
COGS – Royalties related to Corixa	1.8	-	-	-	-	-
COGS – Ameviv divestiture	-	-	36.4	-	-	-
R&D – Pre-merger Biogen net R&D	(301.1)	-	-	-	-	-
R&D – Severance and restructuring	-	3.1	20.3	0.3	1.2	1.2
R&D – Sale of plant	-	-	1.8	-	-	-
R&D – Expenses paid by Cardiokine	-	-	-	-	-	5.2
SG&A – Pre-merger Biogen SG&A	(348.7)	-	-	-	-	-
SG&A – Merger related and purchase accounting costs	-	-	-	0.1	-	-
SG&A – Severance and restructuring	13.2	9.3	19.3	2.0	0.6	3.8
Amortization of intangible assets primarily related to Biogen merger	33.2	347.7	302.3	267.0	257.5	332.7
In-process R&D related to the Biogen Idec merger, acquisitions of Conforma, Syntonic, and Fumapharm, and consolidation of Cardiokine, Neurimmune and Escoubloc and contingent consideration payment in 2006 associated with the 2006 Conforma acquisition	623.0	-	-	330.5	64.2	25.0
Loss/(gain) on settlement of license agreements with Fumedica and Fumapharm	-	-	-	(6.1)	-	-
(Gain)/loss on sale of long lived assets	-	-	111.8	(16.5)	(0.4)	(9.2)
Other income, net: Pre-merger Biogen	32.9	-	-	-	-	-
Other income, net: Gain on sale of long lived assets	-	-	-	-	(7.1)	-
Write down of investments	-	12.7	-	-	-	-
Charitable donations and legal settlements	30.7	-	-	-	-	-
Income taxes: Income tax effect primarily related to reconciling items	(205.8)	(195.4)	(145.2)	(70.3)	(65.5)	(81.9)
Stock option expense	-	-	-	44.5	35.6	29.2
Net Income Attributable to Non-Controlling Interests: Consolidation of Cardiokine and Neurimmune and expenses paid by Cardiokine	-	-	-	-	(65.2)	(5.2)
Non-GAAP Net Income Attributable to Biogen Idec Inc.	431.7	498.0	541.7	776.8	879.1	1,081.0

Notes: The non-GAAP financial measures presented in this table are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Our non-GAAP financial measures are defined as reported, or GAAP, values excluding (1) purchase accounting and merger-related adjustments, (2) stock option expense and the cumulative effect of an accounting change relating to the initial adoption of SFAS No. 123R and (3) other items. Our management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of the Company from year to year and quarter to quarter. Accordingly, we believe investors' understanding of the Company's financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP net income attributable to Biogen Idec Inc and non-GAAP diluted EPS should not be viewed in isolation or as a substitute for reported, or GAAP, net income attributable to Biogen Idec Inc and diluted EPS.

The GAAP figures reflect:

* 2004 and beyond – the combined Biogen Idec

* 2003 – a full year of IDEC Pharmaceuticals and 7 weeks of the former Biogen, Inc. (for the period 11/13/03 through 12/31/03)

Numbers may not foot due to rounding.

Free Cash Flow Reconciliation (\$M)	FY 2004	FY 2005	FY 2006	FY 2007	FY 2008
Net cash flows provided by operating activities	728.0	889.5	841.3	1,020.6	1,564.5
Purchases of property, plant and equipment (Capital Expenditures)	361.0	318.4	198.3	294.1	276.0
Free Cash Flow	367.0	571.1	643.0	736.5	1,288.5

Source: Biogen Idec Annual Reports, 10-K filings and earnings press releases (FY 2003-2008).

biogen idec